Why Belite Bio, Inc’s (BLTE) Stock Is Down 6.54%
As of Wednesday, July 08, Belite Bio, Inc’s BLTE share price has dipped by 6.54%, which has investors questioning if this is right time to buy.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
Commentary & Analysis
Why Belite Bio, Inc’s (BLTE) Stock Is Down 7.56%
As of Tuesday, June 02, Belite Bio, Inc’s BLTE share price has dipped by 7.56%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Belite Bio, Inc’s (BLTE) Stock Is Down 5.61%
As of Friday, April 10, Belite Bio, Inc’s BLTE share price has dipped by 5.61%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Belite Bio, Inc’s (BLTE) Stock Is Up 6.33%
As of Tuesday, March 31, Belite Bio, Inc’s BLTE share price has surged by 6.33%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Belite Bio, Inc’s (BLTE) Stock Is Down 6.21%
As of Monday, March 02, Belite Bio, Inc’s BLTE share price has dipped by 6.21%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | BLTE | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $6,521.7 | $618.0 | 71% |
|
| Shares Out (Mil) | 36.2 | 44.8 | 40% |
|
| Institutional Ownership | 88.8% | 85.3% | 57% |
|
| Float (Mil) | 18.5 | 47.4 | 28% |
|
| Beta | -1.22 | 0.70 | 1% |
|
| Avg Daily Volume (000s) | 193 | 390 | 43% |
|
| Price Change (52-week) |
162.0% | 68.6% | 95% |
|
| Growth | BLTE | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.7% | na |
|
| Net Income (5yr) | (68.0%) | (1.6%) | 4% |
|
| EPS (5yr) | (28.8%) | 14.9% | 9 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | 29.0% | (14.9%) | 85% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 7 | 7 | 7 | |
| Current EPS | ($0.777) | ($2.950) | $2.141 | |
| Month Ago EPS | ($0.817) | ($3.284) | $0.944 | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.865) | ($3.306) | $1.290 | |
| Year/Year Chg | 11.2% | 27.5% | (409.3%) | |
| Financials | BLTE | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $291 | na |
|
| Net Income (TTM) (Mil) | ($78) | ($11) | 13% |
|
| EPS (TTM) | ($2.314) | ($0.700) | 13% |
|
| Operating Cash Flow (TTM) (Mil) | ($37) | ($6) | 11% |
|
| Net Cash Flow (TTM) (Mil) | na | $5 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $6 | 12% |
|
| Enterprise Value (Q1) (Mil) | $5,509 | $450 | 64% |
|
| Valuation | BLTE | Industry Median |
Percentile (All Stocks) |
|
| P/B | 8.27 | 2.78 | 87% |
|
| P/E | na | 17.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | BLTE | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.0% | na |
|
| Net Margin | na | (2.3%) | na |
|
| ROA | (17.7%) | (22.4%) | 21% |
|
| ROE | (18.0%) | (20.2%) | 24% |
|
| Liabilities to Assets | 1.3% | 32.2% | 0% |
|
| F-Score | 4 | 3 | 34% |
|
Belite Bio, Inc did not pass any screens on 8/20/2026.
